Ȩ |  ÁÖ¿ä ÇÁ·Î±×·¥ |  ½ÉÆ÷Áö¾ö |  ÆÄÆ®³Ê¸µ Æ÷·³ |  ¿¬»ç ¾È³» |  ¼îÆ®ÄÚ½º |  ½ºÆù¼­ |  Æ÷½ºÅÍ Á¤º¸ |  °³ÃÖÁö |  ºê·Î¼Å(PDF) | ¹®ÀÇ |  Âü°¡½Åû |  (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼Ç

Call for Speaker Proposals

Á¦1ȸ
De-Risking Drug Discovery
-Drug Discovery ¸®½ºÅ© °æ°¨ ÇÐȸ-

°¢Á¾ Ç¥Àû ¹× ºÐÀÚ ´ë»ó Àü·« ¹× ±â¼ú
2¿ù 21ÀÏ¡­23ÀÏ

À̹ø¿¡ óÀ½À¸·Î °³ÃֵǴ ÀÌ ÇÐȸ¿¡¼­´Â ´ëÇÐ, °ü·Ã ¾÷°è, Á¤ºÎ±â°üÀÇ ´ëÇ¥ÀÚ°¡ ÇÑÀÚ¸®¿¡ ¸ð¿© ÀÓ»óÀü ´Ü°è ¹× ÀÓ»ó ´Ü°è¿¡ ÀÖ´Â ÀǾàǰ Èĺ¸ È­ÇÕ¹°¿¡ °ü ·ÃµÈ ¸®½ºÅ©¸¦ ÁÙÀ̱â À§ÇÑ ÃֽŠÀü·« ¹× ¹æ¹ý, ±â¼ú¿¡ ´ëÇÑ ÀǰßÀ» ±³È¯ÇÕ´Ï´Ù. ¸®½ºÅ© °æ°¨ Àü·«ÀÇ Áøº¸¿¡ ÀÇÇØ ¸®½ºÅ©¸¦ Æò°¡Çϰí, ÀÚ¿ø(»ç¶÷, ÀÚ±Ý, ½Ã °£) ¹èÄ¡¸¦ °³¼±Çϰųª ÀǾàǰÀÇ Àü¹ÝÀûÀÎ ¼Ò¸ðÀ²À» ³·Ãß´Â °Íµµ °¡´ÉÇϳª, ÃæºÐÇÏ´Ù°í ÇÒ ¼ö´Â ¾ø½À´Ï´Ù. ÀÌ ÇÐȸ¿¡¼­´Â ÀúºÐÀÚ ¹× °íºÐÀÚ È­ÇÕ¹°À» Ãë±ÞÇÏ °í ÀÖ´Â Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ºÐ¾ßÀÇ Àü¹®°¡°¡ ÇÑÀÚ¸®¿¡ ¸ð¿© ¸®½ºÅ©¸¦ °æ°¨Çϱâ À§ÇØ À̿밡´ÉÇÑ ÀýÂ÷ ¹× ±â¼ú, ºñÁö´Ï½º¸éÀÇ Á¢±Ù¹ý µîÀ» ºÐ¼®ÇÕ´Ï´Ù . ¶ÇÇÑ ¸®½ºÅ©°¡ ÀÛÀº ¸®µå È­ÇÕ¹°ÀÇ Ã¤Åà ¹× ¸®½ºÅ© °æ°¨ ÇÁ·Î¼¼½ºÀÇ Á¶Á÷³» µµÀÔ, °¢Á¾ ºñÁö´Ï½º ¸ðµ¨ÀÇ Á¢±Ù¹ý°ú À̸¦ À¯È¿ÇÏ°Ô ±â´É½Ã۱â À§ÇÑ ¹æ¹ý, CROÁß Àü¹® Áö½ÄÀ» Ȱ¿ëÇϱâ À§ÇÑ ¹æ¹ý, °³¹ß¿¡ ½ÇÆÐÇÑ ÀǾàǰ ¹× À§Çèµµ°¡ ³ôÀº ÇÁ·ÎÁ§Æ®ÀÇ °¡´É¼ºÀ» È®´ëÇϱâ À§ÇÑ Á¦Ç°ÀÇ À§Ä¡ º¯°æ ¹× ¸ñÀû º¯°æ°ú °°Àº Å׸¶°¡ ´Ù·ç¾îÁö¸ç, Ç¥ÀûÀÇ Á߿伺°ú ºÐÀÚ ¼öÁØ¿¡¼­ÀÇ ¸®½ºÅ© °æ°¨, º¹¼öÀÇ ´Ù¸¥ Àü·«ÀÌ ÇÊ¿äÇÑ ÀÌÀ¯ µîÀ» µÑ·¯½Î°í ³íÀǰ¡ ÁøÇàµË´Ï´Ù. »õ·Î¿î ±â¼ú ¹× ÀÀ ¿ë ±â¼úÀ» »ç¿ëÇϸé Drug Discovery ¸®½ºÅ©¸¦ °³¼±ÇÏ°í ¼Õ½Ç¾×À» Á¶±â¿¡ »êÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. Drug Discovery, ¾à¹° ¾ÈÀü¼º, µ¶¹°ÇÐ, º´ÁøÀÇÇÐ µîÀÇ ºÐ¾ß Àü ¹®°¡°¡ Á¦½ÃÇÏ´Â µ¶ÀÚÀûÀÎ ¹æ¹ý·Ð ¹× °æÇèÀ» °æÃ»Çϰí, °¢Á¾ Çà»çÀå¿¡¼­ °æÇè ¹× Àü¹® Áö½ÄÀ» Á¦½ÃÇϸ鼭 ¾÷°è ¹× Çаè Àü¹®°¡µé°ú ÀθÆÀ» ±¸ÃàÇÒ ¼ö ÀÖ´Â À̹ø ±âȸ¸¦ ³õÄ¡Áö ¸¶½Ã±â ¹Ù¶ø´Ï´Ù.

Who should attend: CRO management, drug discovery leaders, translational scientists, executives, executive scientists, researchers, biomarker experts, and anyone interested in learning novel methods for de-risking.

Topics will include, but are not limited to:

  • De-risking targets
  • De-risking molecules
  • Case studies: small molecules
  • Case studies: large molecules
  • New technologies & novel use of current technologies to expedite/facilitate
  • Safety technologies
  • Screening technologies
  • in vivo models
  • Novel platforms
  • Drug repositioning
  • Drug repurposing
  • Business models
  • Safety evaluations
  • Role of translational medicine
  • Contract research organizations
  • Global strategy discussions
  • Implementation of network pharmacology & translational science

The deadline for submission is July 29, 2011.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


Choose your language
English
Japan
Traditional Chinese
Simplified Chinese

À̺¥Æ® ͏°´õ
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö °ü·Ã ±¹Á¦ÄÁÆÛ·±½º

¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö °ü·Ã ±¹Á¦ÄÁÆÛ·±½º